UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934
Date of Report (Date of earliest event reported):
May 16, 2019
|
SPHERIX INCORPORATED
|
|
|
(Exact Name of Registrant as Specified in Charter)
|
|
Delaware
|
|
0-5576
|
|
52-0849320
|
(State or other jurisdiction
of incorporation)
|
|
(Commission File Number)
|
|
(IRS Employer Identification No.)
|
One Rockefeller Plaza, 11
th
Floor
New York, NY
|
|
|
|
10020
|
(Address of principal executive offices)
|
|
|
|
(Zip Code)
|
Registrant’s telephone number, including
area code: (703) 992-9260
(Former name or former address, if changed
since last report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☒ Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2
of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth
company ☐
If an emerging growth company, indicate
by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
Common Stock, $0.0001 par value
|
SPEX
|
The Nasdaq Capital Market LLC
|
Additional Information
In connection with the proposed transaction
between Spherix Incorporated (“Spherix” or the “Company”) and CBM BioPharma, Inc., a Delaware corporation
(“CBM”) (the “Proposed Transaction”), intends to file a preliminary proxy statement of Spherix. Spherix
will mail a definitive proxy statement and other relevant documents to its stockholders.
Investors and security holders
of Spherix are advised to read, when available, the preliminary proxy statement, and amendments thereto, and the definitive proxy
statement in connection with Spherix’s solicitation of proxies for its special meeting of stockholders to be held to approve
the Proposed Transaction because the proxy statement will contain important information about the Proposed Transaction and the
parties to the Proposed Transaction. The definitive proxy statement will be mailed to stockholders of Spherix as of a record date
to be established for voting on the Proposed Transaction. Shareholders will also be able to obtain copies of the proxy statement,
without charge, once available, at the
SEC’s
website at www.sec.gov
or by directing a request to: Spherix Incorporated, One Rockefeller Plaza, 11
th
Floor, New York, NY 10020.
Participants in the Solicitation
Spherix and CBM and their respective directors,
executive officers, other members of management, and employees, under SEC rules, may be deemed to be participants in the solicitation
of proxies of Spherix’s stockholders in connection with the Proposed Transaction.
Investors and security holders
may obtain more detailed information regarding the names and interests in the Proposed Transaction of Spherix’s directors
and officers in Spherix’s filings with the SEC, including Spherix’s Annual Report on Form 10-K for the year-ended December
31, 2018, which was filed with the SEC on March 14, 2019, Spherix’s Quarterly Report on Form 10-Q for the quarterly period
ended March 31, 2019, which was filed with the SEC on May 15, 2019, and such information will also be in the proxy statement of
Spherix for the Proposed Transaction.
Forward Looking Statements
Certain statements made herein are
not historical facts but are forward-looking statements for purposes of the safe harbor provisions under The Private
Securities Litigation Reform Act of 1995. Forward-looking statements generally are accompanied by words such as
“may”, “should”, “would”, “plan”, “intend”,
“anticipate”, “believe”, “estimate”, “predict”, “potential”,
“seem”, “seek”, “continue”, “future”,
“will”, “expect”, “outlook” or other similar words, phrases or expressions. These
forward-looking statements include statements regarding Spherix’s and CBM’s industry, future events, the proposed
transaction between the parties to the Asset Purchase Agreement, the estimated or anticipated future results and benefits of
the Company following the transaction, including the likelihood and ability of the parties to successfully consummate the
proposed transaction, future opportunities for the combined company, and other statements that are not historical facts.
These statements are based on the current expectations of Spherix’s management and are not predictions of actual
performance. These statements are subject to a number of risks and uncertainties regarding the businesses of Spherix and the
transaction, and actual results may differ materially. These risks and uncertainties include, but are not limited to, changes
in the business environment in which Spherix or CBM operates, including inflation and interest rates, and general financial,
economic, regulatory and political conditions affecting the industry in which Spherix or CBM operates; changes in taxes,
governmental laws, and regulations; competitive product and pricing activity; difficulties of managing growth profitably; the
inability of the parties to successfully or timely consummate the proposed transaction, including the risk that any required
regulatory approvals are not obtained, are delayed or are subject to unanticipated conditions that could adversely affect the
combined company or the expected benefits of the transaction or that the approval of the stockholders of Spherix are not
obtained; failure to realize the anticipated benefits of the transaction, including as a result of a delay in
consummating the transaction or a delay or difficulty in integrating the assets of CBM; uncertainty as to the long-term value
of Spherix’s common stock; those discussed in the Spherix’s Annual Reports on Form 10-K and Quarterly Reports on
Form 10-Q and other documents of Spherix on file with the SEC or in the proxy statement that will be filed with
the SEC by Spherix. There may be additional risks that Spherix presently does not know or that Spherix currently believes are
immaterial that could also cause actual results to differ from those contained in the forward-looking statements. In
addition, forward-looking statements provide Spherix’s expectations, plans or forecasts of future events and views as
of the date of this communication. Spherix anticipates that subsequent events and developments will cause Spherix’s
assessments to change. However, while Spherix may elect to update these forward-looking statements at some point in the
future, Spherix specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as
representing Spherix’s assessments as of any date subsequent to the date of this communication.
Item 8.01 Other Events.
On May
16, 2019, the Company issued a press release announcing: (i) certain results of operations for the fiscal quarter
ended March 31, 2019, and (ii) its restructuring of the terms of the Company’s proposed transaction with CBM
BioPharma, Inc., a Delaware corporation (“CBM”), a copy of which is attached hereto as Exhibit 99.1 and is incorporated
by reference in this Current Report.
Item 9.01. Financial
Statements and Exhibits
d) Exhibits.
The exhibit listed
in the following Exhibit Index is filed as part of this Current Report on Form 8-K.
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
Date: May 16, 2019
|
SPHERIX INCORPORATED
|
|
|
|
|
By:
|
/s/ Anthony Hayes
|
|
|
Name: Anthony Hayes
|
|
|
Title: Chief Executive Officer
|
|
Alkido Pharma (NASDAQ:AIKI)
Historical Stock Chart
From Aug 2024 to Sep 2024
Alkido Pharma (NASDAQ:AIKI)
Historical Stock Chart
From Sep 2023 to Sep 2024